For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Take a look at our BETA site and see what we’ve done so far.
Search and browse selected products
Purchase these through your usual distributor
Unravel complex epigenetic mechanisms implicated in acute myeloid leukemia (AML) with our interactive pathway poster, highlighting key targets in this field and our broad range of proteomic tools against these targets, from recombinant antibodies and proteins to ELISA kits and cell lines.
Published February 08, 2022
Acute myeloid leukemia (AML) is the most common type of leukemia in adults, characterized by uncontrolled proliferation of abnormal myeloid progenitor cells. Epigenetics alterations, such as DNA methylation or histone modifications, are likely to play a critical role in the initiation and progression of AML. Several studies have found that 70% of recurring mutations in patients with AML occur in gene expression regulators, such as epigenetic proteins, transcription factors, and splicing machinery components1-4. Furthermore, several epigenetics therapies, including DNA hypomethylating agents, have been approved by regulatory authorities worldwide or are now undergoing early-phase clinical trials5.
To help you study epigenetic mechanisms in AML, the poster covers all key established and promising epigenetics targets in acute myeloid leukemia, including:
Once you’ve downloaded the poster, click on the highlighted epigenetic targets to access the range of corresponding products.